ADL Bionatur Solutions reports strong financial results for the first quarter of 2019
DGAP-News: ADL Bionatur Solutions / Key word(s): Quarter Results
ADL BIONATUR SOLUTIONS REPORTS STRONG FINANCIAL RESULTS
León, Spain, 07 May 2019 - ADL Bionatur Solutions (MAB: ADL), a company specialized in research and development of health, cosmetic and beauty products, services and industrial fermentation production, today advances the results of selected key performance indicators for the first quarter of 2019 ending March 31, 2019.
"We had a very strong first quarter performance, doubling revenues compared to Q1 2018, and we are set to continue our robust growth path. These good results for the first quarter confirm our path of expansion and profitability, emphasising the great potential of our Company," said Pilar de la Huerta, CEO of ADL Bionatur Solutions.
"Based on our existing CMO contracts, we are expecting the same growth trend for the full year 2019, expecting that our committed capacity of the main fermenters (eight of 225 m3) will grow from 85% to 100% by the end of this year. We anticipate revenues to double compared to 2018, reaching EUR 50-55 million, and accordingly to achieve an overall positive EBITDA for the full year. This marks a major milestone for ADL and consolidates the Company's positive trend initiated in October 2018. We are convinced our achievements will also positively affect the general perception of the company and support the development of the share price."
Key financial figures for the first quarter of 2019:
Financial outlook on 2019
For the fiscal year 2019, ADL Bionatur Solutions expects to generate revenues in the range of EUR 50 million to EUR 55 million, again doubling the Company's turnover. Furthermore, ADL anticipates an overall positive EBITDA for the fiscal year 2019.
2019 year to date highlights:
About ADL Bionatur Solutions
ADL Bionatur Solutions (MAB: ADL) is a company specialized in biopharma manufacturing plus research and development targeting the human microbiome and the animal health sector. The Company, that owns the largest fermentation production plant in Southern Europe, carries out high value-added product development, scale-up and production for third parties. International healthcare companies as well as first-in-class academic and industrial laboratories mainly from Europe and the US are part of ADL's customer base. The biopharma manufacturing business is complemented by a research and development division, which creates a proprietary product pipeline in animal and human health. ADL is listed on the MAB, Spain's Alternative Stock Market (ISIN ES0184980003) and its major shareholder is the investment fund Black Toro Capital holding 73%. More information is available at www.adlbionatur.com
For more Information please contact:
ADL Bionatur Solutions
International Media & Investor Relations
07.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.